12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Torisel temsirolimus: Phase III data

Top-line data from the open-label, international Phase III INTORSECT (B1771003) trial in 512 patients with advanced RCC who failed first-line treatment with Sutent sunitinib showed that once-weekly 25 mg IV Torisel missed the primary endpoint of PFS vs....

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >